Naimesh Solanki1, Tomilowo Abijo1, Carine Galvao1, Philippe Darius1, Kenneth Blum2, Marjorie C Gondré-Lewis3. 1. Department of Anatomy, Howard University, Washington D.C., 20059, USA; Developmental Neuropsychopharmacology Laboratory, Howard University College of Medicine, Washington D.C., 20059, USA. 2. Western University Health Science Center, Graduate School of Biomedical Sciences, Pomona, CA, 91766 USA; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary. 3. Department of Anatomy, Howard University, Washington D.C., 20059, USA; Developmental Neuropsychopharmacology Laboratory, Howard University College of Medicine, Washington D.C., 20059, USA. Electronic address: mgondre-lewis@howard.edu.
Abstract
BACKGROUND: Excessive alcohol intake is a serious but preventable public health problem in the United States and worldwide. Alcohol and other substance use disorders occur co-morbid with more generalized reward deficiency disorders, characterized by a reduction in dopamine (DA) signaling within the reward pathway, and classically associated with increased impulsivity, risk taking and subsequent drug seeking behavior. It is postulated that increasing dopamine availability and thus restoring DA homeostasis in the mesocorticolimbic system could reduce the motivation to seek and consume ethanol. Here, we treated animals with a neuro-nutrient, KB220Z also known as Synaptamine, designed to augment DA signaling. METHOD: KB220Z was administered to genetically alcohol-preferring (P) adult male and female rats by oral gavage (PO), intraperioneally (IP), or subcutaneously (SQ) for 4 consecutive days at a 3.4 mL/Kg rat equivalent dose and compared to saline (SQ, IP) or water (PO) controls. Subsequent to treatment, lever pressing and consumption of 10 % ethanol or control 3% sucrose during operant responding was assessed using a drinking in the dark multiple scheduled access (DIDMSA) binge drinking protocol. Locomotor and elevated zero maze activity, and DRD2 mRNA expression via in situ hybridization (ISH) were assessed independently following 4 days of a SQ regimen of KB220Z. RESULTS: KB220Z administered via IP and SQ markedly and immediately reduced binge drinking of 10 % ethanol in both male and female rats whereas PO administration took at least 3 days to decrease lever pressing for ethanol in both male and female rats. There was no effect of SQ KB220Z on 3% sucrose drinking. Elevated activity in the open field was significantly decreased, and time spent in the open arm of the EZM was moderately reduced. The regimen of SQ KB220Z did not impact the number of DRD2 punctae in neurons of the NAc, but the NAc shell expressed more DRD2 mRNA/cell than NAc core independent of KB220Z. CONCLUSION: KB220Z attenuates ethanol drinking and other RDS behaviors in P rats possibly by acting on the dopaminergic system, but not by effecting an increase in NAc DRD2 mRNA expression.
BACKGROUND: Excessive alcohol intake is a serious but preventable public health problem in the United States and worldwide. Alcohol and other substance use disorders occur co-morbid with more generalized reward deficiency disorders, characterized by a reduction in dopamine (DA) signaling within the reward pathway, and classically associated with increased impulsivity, risk taking and subsequent drug seeking behavior. It is postulated that increasing dopamine availability and thus restoring DA homeostasis in the mesocorticolimbic system could reduce the motivation to seek and consume ethanol. Here, we treated animals with a neuro-nutrient, KB220Z also known as Synaptamine, designed to augment DA signaling. METHOD:KB220Z was administered to genetically alcohol-preferring (P) adult male and female rats by oral gavage (PO), intraperioneally (IP), or subcutaneously (SQ) for 4 consecutive days at a 3.4 mL/Kg rat equivalent dose and compared to saline (SQ, IP) or water (PO) controls. Subsequent to treatment, lever pressing and consumption of 10 % ethanol or control 3% sucrose during operant responding was assessed using a drinking in the dark multiple scheduled access (DIDMSA) binge drinking protocol. Locomotor and elevated zero maze activity, and DRD2 mRNA expression via in situ hybridization (ISH) were assessed independently following 4 days of a SQ regimen of KB220Z. RESULTS:KB220Z administered via IP and SQ markedly and immediately reduced binge drinking of 10 % ethanol in both male and female rats whereas PO administration took at least 3 days to decrease lever pressing for ethanol in both male and female rats. There was no effect of SQ KB220Z on 3% sucrose drinking. Elevated activity in the open field was significantly decreased, and time spent in the open arm of the EZM was moderately reduced. The regimen of SQ KB220Z did not impact the number of DRD2 punctae in neurons of the NAc, but the NAc shell expressed more DRD2 mRNA/cell than NAc core independent of KB220Z. CONCLUSION:KB220Z attenuates ethanol drinking and other RDS behaviors in P rats possibly by acting on the dopaminergic system, but not by effecting an increase in NAcDRD2 mRNA expression.
Authors: Harry L June; Juan Liu; Kaitlin T Warnock; Kimberly A Bell; Irina Balan; Dominique Bollino; Adam Puche; Laure Aurelian Journal: Neuropsychopharmacology Date: 2015-01-08 Impact factor: 7.853
Authors: K Blum; M C Trachtenberg; C E Elliott; M L Dingler; R L Sexton; A I Samuels; L Cataldie Journal: Alcohol Date: 1988 Nov-Dec Impact factor: 2.405
Authors: Juan Liu; Andrew R Yang; Timothy Kelly; Adam Puche; Chioma Esoga; Harry L June; Ahmed Elnabawi; Istvan Merchenthaler; Werner Sieghart; Harry L June; Laure Aurelian Journal: Proc Natl Acad Sci U S A Date: 2011-02-28 Impact factor: 11.205
Authors: Anna K Radke; Isabel T Held; Elizabeth A Sneddon; Collin A Riddle; Jennifer J Quinn Journal: Addict Biol Date: 2019-10-27 Impact factor: 4.280
Authors: Kenneth Blum; Mark S Gold; Jean L Cadet; David Baron; Abdalla Bowirrat; Panayotis K Thanos; Raymond Brewer; Rajendra D Badgaiyan; Marjorie C Gondré-Lewis Journal: Curr Psychopharmacol Date: 2021-01-08
Authors: Kenneth Blum; Mark S Brodie; Subhash C Pandey; Jean Lud Cadet; Ashim Gupta; Igor Elman; Panayotis K Thanos; Marjorie C Gondre-Lewis; David Baron; Shan Kazmi; Abdalla Bowirrat; Marcelo Febo; Rajendra D Badgaiyan; Eric R Braverman; Catherine A Dennen; Mark S Gold Journal: J Pers Med Date: 2022-06-20
Authors: Kenneth Blum; Ali Raza; Tiffany Schultz; Rehan Jalali; Richard Green; Raymond Brewer; Panyotis K Thanos; Thomas McLaughlin; David Baron; Abdalla Bowirrat; Igor Elman; B William Downs; Debasis Bagchi; Rajendra D Badgaiyan Journal: Acta Sci Neurol Date: 2021-02-02
Authors: B W Downs; K Blum; D Bagchi; S Kushner; M Bagchi; J M Galvin; McG Lewis; D Siwicki; R Brewer; B Boyett; D Baron; J Giordano; R D Badgaiyan Journal: J Syst Integr Neurosci Date: 2020-04-30
Authors: Kenneth Blum; Shan Kazmi; Edward J Modestino; Bill William Downs; Debasis Bagchi; David Baron; Thomas McLaughlin; Richard Green; Rehan Jalali; Panayotis K Thanos; Igor Elman; Rajendra D Badgaiyan; Abdalla Bowirrat; Mark S Gold Journal: J Pers Med Date: 2021-03-16
Authors: Kenneth Blum; Bruce Steinberg; Marjorie C Gondre-Lewis; David Baron; Edward J Modestino; Rajendra D Badgaiyan; B William Downs; Debasis Bagchi; Raymond Brewer; Thomas McLaughlin; Abdalla Bowirrat; Mark Gold Journal: Psychol Res Behav Manag Date: 2021-12-17